Biopharma firm AusperBio secures $120m Series C funding

Biopharma firm AusperBio secures $120m Series C funding

Photo from AusperBio

31 August, 2026

Edited by: Paramita Chatterjee

AHB-137 AusperBio biopharmaceutical chronic hepatitis B (CHB)Hangzhou Hankang Capital Qiming Venture Partners RA Capital Management

Printed by Unregistered user on Thu, 15 Oct 2026 11:42:04 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Sino Biopharma buys Hangzhou Hygieia Biomedical for up to $172m

Shanghai state investor signs 10 new GPs to fund biopharma innovations with ‘patient capital’

Read more from Greater China

These were our top stories in September 2026

Baicha Baidao notes trading suspension over IPO rigging concerns